Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
Schizophrenia, Allopurinol, Add-on-treatment
Brief summary
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.
Detailed description
An emerging body of evidence supports a purinergic hypothesis for schizophrenia. Adenosine agonists have been shown to have properties similar to those of dopamine antagonists and there is a well characterized antagonistic interaction between adenosine and dopamine receptors in the ventral striatum1. Increased adenosinergic transmission has been demonstrated to reduce the affinity of dopamine agonists for dopamine receptors. It has been theorized that adenosine may exert some of its antipsychotic effects through modulation of glutamatergic transmission. Three double-blind, randomized, placebo-controlled trials have showed statistically significant greater improvements in PANSS scores in the allopurinol groups vs. placebo groups. These empiric data, together with the theoretical and basic science background cited, provide the impetus for this proposed study.
Interventions
DRUGAllopurinol
Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
Sponsors
Sheba Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, 18-65 years of age, inclusive 2. Because gout is relatively rare in women of childbearing age, there are few reports describing the use of allopurinol during pregnancy; in those there were no adverse fetal outcomes attributable to allopurinol. Therefore, only females who are abstinent or practicing an established method of birth control (oral contraceptive tablets, hormonal implant device, hormone patch, injectable contraceptive, intrauterine device \[IUD\]) can be included in the trial. 3. Willing and able to provide informed consent, after the nature of the study has been fully explained 4. Current DSM-IV-TR diagnosis of schizophrenia as confirmed by SCID 5. Symptoms: 4 (moderate) or above on CGI-S AND \>= 4 (moderate) score on two of the following four PANSS items: delusions, hallucinatory behaviors, conceptual disorganization or suspiciousness/ persecution. 6. Must be on any antipsychotic drug for at least 2 weeks prior to the baseline visit, at doses within the PORT criteria. Patients receiving higher doses will have their records reviewed to insure that dose is required. Patients receiving two anti-psychotics, or IM depot antipsychotics can also be included. 7. Inpatients or outpatients.
Exclusion criteria
1. Unwilling or unable, in the opinion of the Investigator, to comply with study instructions 2. Pregnant or breast-feeding 3. Unstable medical disease (malignancy, poorly controlled diabetes, active ischemic cardiac disease, or cardiomyopathy, serious pulmonary disease, , kidney disease, impaired liver functioning 4. Likely allergy or sensitivity to allopurinol 5. At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others. 6. Suffers from a significant Substance Dependence disorder based on DSM-IV criteria within the 3 months prior to Screening, or is deemed by the Investigator to have a high risk of substance use during the study. Patients with a history of recreational use of cannabinoids or alcohol, and/or patients who smoke cigarettes can be included. 7. Concurrent delirium, mental retardation, drug-induced psychosis, or history of brain trauma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS total score. | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| PANSS positive, negative and general psychopathology scales, BACS, CGI, Simpson-Angus Scale. | 6 weeks |
Countries
Israel, Romania
Outcome results
None listed